Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Corporate Update and First Quarter 2017 Financial Results

LEXINGTON, MA--(Marketwired - May 8, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehydes, today announced it will provide a corporate update and issue financial results for the quarter ended March 31, 2017, on Monday, May 15, 2017, prior to the market open.

Aldeyra will hold a conference call on Monday, May 15, 2017, at 8:00 a.m. EDT to discuss the results. The dial-in numbers are 1-719-457-2600 for domestic callers and 1-888-283-6901 for international callers. The conference ID number for both is 6322395. A live webcast of the conference call will also be available on the investor relations page of the Aldeyra Therapeutics corporate website at www.aldeyra.com .

After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for one year. In addition, a telephonic replay of the call will be available until May 14, 2018. The replay dial-in numbers are 1-888-203-1112 for domestic callers and 1-719-457-0820 for international callers. Please use event passcode 6322395.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. Aldeyra's lead product candidate, ADX-102, is an aldehyde trap in development for ocular inflammation, as well as for Sjögren-Larsson Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of aldehyde metabolism. Aldeyra's product candidates have not been approved for sale in the U.S. or elsewhere.

Contact Information:

Corporate Contact:

Stephen Tulipano

Aldeyra Therapeutics, Inc.

Tel: +1 781-761-4904 ext. 205

Investor Contact:

Chris Brinzey

Westwicke Partners

Tel: 339-970-2843

Media Contact:

Cammy Duong

MacDougall Biomedical Communications

781-591-3443